Tiziano Barbui

4 weeks ago | nature.com | Claire Harrison |Tiziano Barbui |Prithviraj Bose

AbstractPolycythaemia vera (PV) is a haematological malignancy in the myeloproliferative neoplasm family. PV is typically characterized by erythrocytosis and often leukocytosis and thrombocytosis1. Clinical features include reduced life expectancy due to hazards of thrombosis (often in atypical sites), haemorrhage and transformation to myelofibrosis and less frequently to a form of acute myeloid leukaemia called blast phase.

2 months ago | nature.com | Daniel A. Arber |Ayalew Tefferi |Alessandro Vannucchi |Tiziano Barbui

AbstractA lively discussion persists regarding the diagnostic criteria for essential thrombocythemia (ET), primary myelofibrosis (PMF) and polycythemia vera (PV), particularly in relation to early/pre-fibrotic myelofibrosis (pre-PMF), a disease entity initially introduced in 2001 by the 3rd edition of the World Health Organization (WHO) classification. The definition and criteria used to diagnose pre-PMF have been progressively modified over time.

Nov 5, 2024 | nature.com | Tiziano Barbui |Alessandra Carobbio |Alessandro Vannucchi |Paola Guglielmelli |Alessandro Rambaldi |Naseema Gangat

AbstractWe analyzed the neutrophil-to-lymphocyte ratio (NLR) in 1508 patients with PV and found that those with an NLR ≥ 5 were generally older, had a longer disease history, and had higher cardiovascular risk factors, more arterial thrombosis, and more aggressive blood counts, indicating a more proliferative disease.

Oct 24, 2024 | nature.com | Tiziano Barbui |Alessandra Carobbio |Valerio De Stefano |Alessandro Rambaldi |Ayalew Tefferi

AbstractThis viewpoint summarizes findings from analyses of large personal patient databases of myeloproliferative neoplasms (MPNs) to assess the impact of thrombosis on mortality, disease progression, and second cancers (SC). Despite advances, the current incidence of arterial and venous thrombosis remains a challenge.

Jan 22, 2024 | nature.com | Tiziano Barbui

Over the past two decades, significant progress has been made in several areas of Philadelphia chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs), namely polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF). The driver mutations in the JAK2-V617, MPL, calreticulin opened new diagnostic and prognostic possibilities and provided new targets for therapy [1].